Non-cirrhotic Intrahepatic Portal Hypertension: Associated Gut Diseases and Prognostic Factors
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Non-cirrhotic intrahepatic portal hypertension (NCIPH) is generally regarded to have a benign prognosis. We have studied a cohort followed-up at a tertiary referral center and postulate that gut-derived prothrombotic factors may contribute to the pathogenesis and prognosis of NCIPH.
We retrospectively analyzed prognostic indicators in 34 NCIPH patients. We also searched for associated gut diseases.
Transplant-free survival in NCIPH patients from first presentation with NCIPH at 1, 5, and 10 years was 94% (SE: 4.2%), 84% (6.6%), and 69% (9.8%), respectively. Decompensated liver disease occurred in 53% of patients. Three (9%) patients had ulcerative colitis while five of 31 (16%) tested had celiac disease and on Kaplan–Meier analysis, celiac disease predicted reduced transplant-free survival (p = 0.018). On multivariable Cox regression analysis, independent predictors of reduced transplant-free survival were older age at first presentation with NCIPH, hepatic encephalopathy, and portal vein thrombosis. Prevalence of elevated initial serum IgA anticardiolipin antibody (CLPA) was significantly higher in NCIPH (36% of patients tested), compared to Budd–Chiari syndrome (6%) (p = 0.032, Fisher’s exact test) and celiac disease without concomitant liver disease (0%) (p = 0.007).
We have identified prognostic factors and report progression to liver failure in 53% of NCIPH patients followed-up at our center. Our data supports a role for intestinal disease in the pathogenesis of intrahepatic portal vein occlusion leading to NCIPH.
- Krasinskas AM, Eghtesad B, Kamath PS, Demetris AJ, Abraham SC. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl. 2005;6:627–634. CrossRef
- Hillaire S, Bonte E, Denninger MH, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension in the West: a re-evaluation in 28 patients. Gut. 2002;2:275–280. CrossRef
- Sarin SK, Kapoor D. Non-cirrhotic portal fibrosis: current concepts and management. J Gastroenterol Hepatol. 2002;5:526–534. CrossRef
- Henderson JM. Liver transplantation for severe intrahepatic noncirrhotic portal hypertension. Liver Transpl. 2005;6:610–611. CrossRef
- Boyer JL, Hales MR, Klatskin G. “Idiopathic” portal hypertension due to occlusion of intrahepatic portal veins by organized thrombi. A study based on postmortem vinylite-injection corrosion and dissection of the intrahepatic vasculature in 4 cases. Medicine (Baltimore). 1974;1:77–91.
- Wanless IR, Godwin TA, Allen F, Feder A. Nodular regenerative hyperplasia of the liver in hematologic disorders: a possible response to obliterative portal venopathy. A morphometric study of nine cases with an hypothesis on the pathogenesis. Medicine (Baltimore). 1980;5:367–379.
- Kingham JG, Levison DA, Stansfeld AG, Dawson AM. Non-cirrhotic intrahepatic portal hypertension: a long-term follow-up study. Q J Med. 1981;199:259–268.
- Nakanuma Y, Hoso M, Sasaki M, et al. Histopathology of the liver in non-cirrhotic portal hypertension of unknown aetiology. Histopathology. 1996;3:195–204. CrossRef
- Austin A, Campbell E, Lane P, Elias E. Nodular regenerative hyperplasia of the liver and coeliac disease: potential role of IgA anticardiolipin antibody. Gut. 2004;7:1032–1034. CrossRef
- Sawada S, Sato Y, Aoyama H, Harada K, Nakanuma Y. Pathological study of idiopathic portal hypertension with an emphasis on cause of death based on records of annuals of pathological autopsy cases in Japan. J Gastroenterol Hepatol. 2007;22(2):204–209. CrossRef
- Dhiman RK, Chawla Y, Vasishta RK, et al. Non-cirrhotic portal fibrosis (idiopathic portal hypertension): experience with 151 patients and a review of the literature. J Gastroenterol Hepatol. 2002;1:6–16. CrossRef
- Wanless IR, Wong F, Blendis LM, Greig P, Heathcote EJ, Levy G. Hepatic and portal vein thrombosis in cirrhosis: possible role in development of parenchymal extinction and portal hypertension. Hepatology. 1995;5:1238–1247.
- Sarin SK, Sethi KK, Nanda R. Measurement and correlation of wedged hepatic, intrahepatic, intrasplenic and intravariceal pressures in patients with cirrhosis of liver and non-cirrhotic portal fibrosis. Gut. 1987;3:260–266. CrossRef
- Hagiwara C, Tanaka M, Kudo H. Increase in colorectal epithelial apoptotic cells in patients with ulcerative colitis ultimately requiring surgery. J Gastroenterol Hepatol. 2002;7:758–764. CrossRef
- Cancado EL, Medeiros DM, Deguti MM, et al. Celiac disease associated with nodular regenerative hyperplasia, pulmonary abnormalities, and IgA anticardiolipin antibodies. J Clin Gastroenterol. 2006;2:135–139. CrossRef
- Ross AG, Bartley PB, Sleigh AC, et al. Schistosomiasis. N Engl J Med. 2002;346:1212–1220. Review. CrossRef
- Mazumder DN. Effect of chronic intake of arsenic-contaminated water on liver. Toxicol Appl Pharmacol. 2005;206:169–175. CrossRef
- Nevens F, Fevery J, Van Steenbergen W, Sciot R, Desmet V, De Groote J. Arsenic and non-cirrhotic portal hypertension. A report of eight cases. J Hepatol. 1990;11:80–85. CrossRef
- Geubel AP, De Galocsy C, Alves N, Rahier J, Dive C. Liver damage caused by therapeutic vitamin A administration: estimate of dose-related toxicity in 41 cases. Gastroenterology. 1991;100:1701–1709.
- Daniel F, Cadranel JF, Seksik P, et al. Azathioprine induced nodular regenerative hyperplasia in IBD patients. Gastroenterol Clin Biol. 2005;29:600–603. CrossRef
- Ravikumara M, Hill FG, Wilson D, et al. C6-Thioguanine-related chronic hepatotoxicity and variceal haemorrhage in children treated for acute lymphoblastic leukaemia–a dual-centre experience. J Pediatr Gastroenterol Nutr. 2006;42:535–538. CrossRef
- de Boer NK, Reinisch W, Teml A, Dutch 6-TG working group, et al. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion. 2006;73:25–31. Epub 2006 Feb 21. Review. CrossRef
- Perez Ruiz F, Orte Martinez FJ, Zea Mendoza AC, Ruiz del Arbol L, Moreno Caparros A. Nodular regenerative hyperplasia of the liver in rheumatic diseases: report of seven cases and review of the literature. Semin Arthritis Rheum. 1991;21:47–54. Review. CrossRef
- Ward C, Lucas M, Piris J, Collier J, Chapel H. Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia. Clin Exp Immunol. 2008;153:331–337. Epub 2008 Jul 18. CrossRef
- Malamut G, Ziol M, Suarez F, et al. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol. 2008;48:74–82. Epub 2007 Oct 17. CrossRef
- Wanless IR, Peterson P, Das A, Boitnott JK, Moore GW, Bernier V. Hepatic vascular disease and portal hypertension in polycythemia vera and agnogenic myeloid metaplasia: a clinicopathological study of 145 patients examined at autopsy. Hepatology. 1990;12:1166–1174. CrossRef
- Madhu K, Ramakrishna B, Zachariah U, Eapen CE, Kurian G. Non-cirrhotic intrahepatic portal hypertension. Gut. 2008;57:1529. CrossRef
- Roskams T, Baptista A, Bianchi L, et al. Histopathology of portal hypertension: a practical guideline. Histopathology. 2003;42(1):2–13. Review. CrossRef
- Madhu K, Avinash B, Ramakrishna B, et al. Idiopathic non-cirrhotic intrahepatic portal hypertension: common cause of cryptogenic intrahepatic portal hypertension in a Southern Indian tertiary hospital. Indian J Gastroenterol. 2009;28:83–87. Epub 2009 Nov 12. CrossRef
- Non-cirrhotic Intrahepatic Portal Hypertension: Associated Gut Diseases and Prognostic Factors
Digestive Diseases and Sciences
Volume 56, Issue 1 , pp 227-235
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Non-cirrhotic portal hypertension
- Celiac disease
- Inflammatory bowel disease
- IgA cardiolipin antibody
- Portal vein thrombosis
- Industry Sectors
- Author Affiliations
- 1. Liver Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK
- 6. Department of GI Sciences, Liver Unit, Christian Medical College, Vellore, Tamil Nadu, 632004, India
- 2. Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK
- 3. Department of Pathology, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK
- 4. Clinical Immunology, Division of Immunology and Infection, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK
- 5. Department of Immunology, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK
- 7. Department of Anaesthesiology and Intensive Care Medicine, University Hospital of Patras, 26500, Rion, Greece